Sabizabulin, a new COVID-19 therapeutic with a novel mechanism of action, seems to be making a splash among drug regulators around the world. A review of the product has just started in the EU under the European Medicines Agency’s expanded remit, an application for emergency use authorization has been filed in the US, and an expedited assessment is on the cards in the UK.
Coronavirus Notebook: Veru’s Sabizabulin Prioritized By European & US Regulators, Kinarus’s KIN001 Offers ‘Synergistic Efficacy’
Sabizabulin is the first product to be assessed under the European Medicines Agency’s expanded mandate, and has also been filed for a US emergency use authorization. At global level, the World Health Organization has issued new guidance on the use of second booster doses of COVID-19 vaccines.
